Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide crossover study in cystic fibrosis-related diabetes and impaired glucose tolerance
ACTRN12615001029583Phase 3Completed
- Sponsor
- Jennifer Couper
- Start
- Mar 2016
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, double-blind trial of exenatide in cystic fibrosis-related diabetes (CFRD) and prediabetes (2 arms), sponsored by Jennifer Couper. Primary endpoint: Postprandial glycaemia. Started Mar 2016; status: completed.
02
Drugs
exenatide
03
Conditions
cystic fibrosis-related diabetes (CFRD)prediabetes
Beyond the preview
Go deeper on ACTRN12615001029583.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12615001029583.